Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, David T. Rubin et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
S1429 Efficacy of Guselkumab in Moderately to Severely Active Crohn’s Disease According to Induction Clinical Response Status: Week 48 Results from the GALAXI 2 & 3 Phase 3 TrialsAnita Afzali, Geert D’Haens, Julián Panés et al.|The American Journal of Gastroenterology|2024Cited by 0